Synthetic polymers in 21st century therapeutics: The way forward

Drug Discovery Today

Volumn 8, Issue 4, 2003, Pages 154-156

  Hunter, A Christy ^a   Moghimi, S Moein ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Chemical Biology; Drug Discovery; Pharmaceutical Science; Synthetic polymers; Toxicity

Indexed keywords

ANTIBODY; LIPOSOME; MACROGOL; POLYMER; POLYSACCHARIDE; RECEPTOR PROTEIN; SIALIC ACID DERIVATIVE;

ANTIGEN ANTIBODY REACTION; CELL ACTIVITY; CHEMICAL ENGINEERING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG INDUSTRY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IMMUNOGENICITY; IMMUNOTOXICITY; MACROMOLECULE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; NOTE; PROTEIN EXPRESSION; TOXICITY TESTING;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNE SYSTEM; POLYETHYLENE GLYCOLS; POLYMERS; POLYSACCHARIDES;

EID: 0037441531     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02605-9     Document Type: Note

References (21)

1. Hunter A.C., Moghimi S.M. Therapeutic synthetic polymers: a game of Russian Roulette? Drug Discov. Today. 7:2002;998-1001.
2. Pardridge W.M. Formulation of therapeutic polymers for drug and gene delivery. Drug Discov. Today. 7:2002;1120-1121.
3. Phillips R.O. Polymers for drug delivery: more research needed. Drug Discov. Today. 8:2003;17-18.
4. Davis S.S. Parenteral polymers. Drug Discov. Today. 7:2002;1159-1161.
5. Eaton M. Polymer therapeutics - what is missing? Drug Discov. Today. 7:2002;1203-1204.
6. Goldman M., et al. How to predict adverse immune reactions induced by pharmaceutical compounds. Trends Biotechnol. 13:1995;283-285.
7. Hugger E.D., et al. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J. Pharm. Sci. 91:2002;1980-1990.
8. King M., et al. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat. Neurosci. 4:2001;268-274.
9. Roland P.J. MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides. 22:2001;2015-2020.
10. Szebeni J., et al. Role of complement activation in hypersensitivity reactions to Doxil® and hynic PEG liposomes: experimental and clinical studies. J. Liposome Res. 12:2002;165-172.
11. Bradley A.J., et al. Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs. Transfusion. 41:2001;1225-1233.
12. Hunter, A.C. et al. (2002) Determination of human serum complement activation by commercial, clinical and chemically modified block copolymer poloxamer 188. Abstr. Pap. Am. Chem. S. 224: 406-POLY Part 2, 18 August 2002.
13. Moghimi S.M., Hunter A.C. Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug. 18:2001;527-550.
14. Brocchini S. Polymers in medicine: a game of chess. Drug Discov. Today. 8:2003;111-112.
15. Bacon A. Polymers - a synthetic or natural choice? Drug Discov. Today. 7:2002;1202-1203.
16. Moghimi S.M., et al. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53:2001;283-318.
17. 197 via adipic acid dihydrazide. Vaccine. 1:1995;463-470.
18. Gregson N.A., et al. Monoclonal antibodies against meningococcal polysaccharide with cross-reactivity against brain antigens. Biochem. Soc. Trans. 13:1985;462.
19. Devi J.N., et al. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. 65:1997;1045-1052.
20. Crocker P.R., et al. Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. EMBO J. 10:1991;1661-1669.
21. Munday J., et al. Sialic acid binding receptors (siglecs) expressed by macrophages. J. Leukoc. Biol. 66:1999;705-771.